WAYNE, Pa. and MISGAV, Israel, April 9, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) (AIM:MEDU) (AIM:MEDG), the developer of Biopump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that all resolutions proposed at the Company’s Annual Meeting of Stockholders held yesterday were duly passed.
Help employers find you! Check out all the jobs and post your resume.
